NCT04904913View on ClinicalTrials.gov

A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

328

Participants

Timeline

Start Date

June 8, 2021

Primary Completion Date

March 29, 2023

Study Completion Date

December 6, 2023

Conditions
Overweight/ Obesity
Interventions
DRUG

IBI362

IBI362 administered subcutaneously (SC) once a week.

OTHER

placebo

placebo administered subcutaneously (SC) once a week.

Trial Locations (1)

100044

Peking University people's hospital, Beijing

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY